JP Morgan Initiates Halozyme Therapeutics With Outperform

Analysts at JP Morgan initiated coverage on Halozyme Therapeutics

with a Outperform rating. The target price for Halozyme Therapeutics is set to $13. Halozyme Therapeutics shares have gained 10.07% over the past 52 weeks, while the S&P 500 index has surged 16.93% in the same period. Halozyme Therapeutics' shares fell 2.82% to close at $9.29 yesterday.